It is possible, although unlikely, that the high glucose levels and metabolic disturbance before the start of insulin therapy might trigger leukemia, in an analogous fashion to the increased risk of cancer associated with type 2 diabetes [25]. The gene discussed is INS; the disease is leukemia.